Physician profile
Olga S Freeman
NPI 1306848726
$2,079.34
in general payments reported to CMS, 2019-2025
27 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $433 · 2021: $293 · 2022: $324 · 2023: $160 · 2024: $330 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $524.62 | 2019-2023 | Tresiba, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $286.66 | 2019-2024 | Breztri, Farxiga |
| Inspire Medical Systems, INC. | $201.86 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $130.62 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $115.15 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $114.81 | 2019-2024 | Livalo |
| Abbvie INC. | $93.97 | 2021-2023 | |
| Lilly USA, LLC | $84.30 | 2022-2024 | Mounjaro |
| Amgen INC. | $55.20 | 2019-2024 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $44.69 | 2019 | |
| Nevro Corp. | $42.63 | 2022 | |
| Radius Health, INC. | $40.61 | 2019-2025 | Tymlos |
| Pfizer INC. | $39.32 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $30.45 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.54 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $29.35 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $24.68 | 2020 | |
| Esperion Therapeutics, INC. | $21.37 | 2020 | |
| Daiichi Sankyo INC. | $20.71 | 2021 | |
| Dexcom, INC. | $19.87 | 2022 | |
| Sumitomo Pharma America, INC. | $18.07 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $15.65 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.60 | 2019 | |
| Almatica Pharma LLC | $14.23 | 2023 | Gralise, Loreev Xr |
| Eisai INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.